The following abstracts represent the presentations given at IWWM-9 (Amsterdam-2016), Session 5: Plenary Talks:

Session Chairs: Pierre Morel (France) and Marvin Stone (USA)

Molecular basis of ibrutinib resistance in WM. L. Xu (USA)

CXCR4 mutations are associated with more advanced disease and shorter time to first treatment in patients with WM. M. Varettoni (Italy)

Evaluation of a WM-specific flow cytometry assay for diagnosis and disease response assessment. R. de Tute (UK)

Characterization of molecular abnormalities in WM. D. Roos-Weil (France)

R2W: Subcutaneous BCR versus FCR for initial therapy of WM: a randomized phase II study. R. Auer (UK)